Introduction
============

Ankylosing spondylitis (AS), a subtype of spondyloarthritis (Online Mendelian Inheritance in Man, ref no. 106300; <https://www.omim.org/entry/106300>), is a progressive chronic disease characterized by inflammatory lower back pain, and is occasionally accompanied by peripheral arthritis, enthesis, iritis, spinal deformity and ankyloses ([@b1-mmr-16-05-6532],[@b2-mmr-16-05-6532]). AS is highly heritable (\>90%) and demonstrates an estimated prevalence of 0.1--0.4% in the Caucasian population and 0.2--0.54% in the Chinese population ([@b3-mmr-16-05-6532],[@b4-mmr-16-05-6532]).

Previous studies have indicated that AS is strongly associated with the human leukocyte antigen-B27 gene ([@b3-mmr-16-05-6532],[@b5-mmr-16-05-6532]), a haplotype of the major histocompatibility complex (MHC). However, additional studies have suggested that non-MHC genes may be involved ([@b6-mmr-16-05-6532]--[@b8-mmr-16-05-6532]). Recently, according to the first genome-wide association study of AS in a Caucasian population, endoplasmic reticulum aminopeptidase 1 (*ERAP1*; also known as *ARTS1*), located on chromosome 5q15, has been demonstrated to serve an important role in the risk of developing AS ([@b7-mmr-16-05-6532]). Subsequently, a number of European and Asian studies have attempted to replicate this study using different single nucleotide polymorphisms (SNPs), and associations have been reported in different populations ([@b1-mmr-16-05-6532],[@b9-mmr-16-05-6532]--[@b17-mmr-16-05-6532]). However, a number of case-control studies have failed to report this association using the same genetic markers ([@b4-mmr-16-05-6532],[@b18-mmr-16-05-6532]--[@b20-mmr-16-05-6532]). Potential rationales for these inconsistent results include ethnic differences between populations, the heterogeneity of AS and inadequate statistical power in certain studies. These inconsistencies may be overcome by performing a meta-analysis, which provides a quantitative approach for combining different independent studies and may maximize the overall statistical power ([@b21-mmr-16-05-6532],[@b22-mmr-16-05-6532]).

There are \>13 known AS-associated SNPs that span the *ERAP1* gene locus, including rs3734016, rs26653, rs27895, rs2287987, rs27434, rs30187, rs10050860, rs17482078, rs27044, rs1065407, rs27980, rs7711564 and rs27037, which have been used as genetic markers in multiple association studies ([@b1-mmr-16-05-6532],[@b7-mmr-16-05-6532],[@b9-mmr-16-05-6532]--[@b20-mmr-16-05-6532]). A total of 8 SNPs (rs3734016, rs26653, rs27895, rs2287987, rs30187, rs10050860, rs17482078 and rs27044) are non-synonymous substitutions in the coding region of the *ERAP1* gene, which implies that the corresponding amino acid substitutions exhibit functional effects ([@b9-mmr-16-05-6532],[@b11-mmr-16-05-6532]).

In the present study, a two-stage bioinformatics analysis was performed in order to investigate the role of common genetic variants of *ERAP1* in AS. In the first stage, a classical meta-analysis was used to assess all of the AS-associated SNPs in *ERAP1*, using all published case-control association studies. In the second stage, the functional effects of these genetic variants of *ERAP1* were investigated using protein structure analysis.

Materials and methods
=====================

### Literature search

To identify studies for inclusion in the meta-analysis, PubMed (<http://www.ncbi.nlm.nih.gov>), Scopus (<http://www.scopus.com>) and Embase (<http://www.elsevier.com/online-tools/embase>) citations up to June 2016 were queried with the following search terms: 'ERAP1', 'endoplasmic reticulum aminopeptidase 1', 'ARTS1', 'Ankylosing spondylitis' and 'AS'. The retrieved abstracts were read to identify studies that examined the association between a polymorphism in the *ERAP1* gene locus and AS. Studies of this type were subsequently read in full to assess their appropriateness for inclusion in the meta-analysis. All references cited in these studies were reviewed to identify additional studies not indexed by PubMed, Scopus and Embase.

### Inclusion criteria, exclusion criteria and data extraction

Only studies that tested ≥1 polymorphism within the *ERAP1* gene locus were included in the current meta-analysis. In addition, studies that m*et al*l of the following criteria were included: i) Publication in a peer-reviewed journal; ii) publication in English; iii) presentation of original data on genotype and/or alleles in case and control samples; iv) independence from other studies (i.e. studies that included and re-analyzed a previously published data set were not regarded as independent, and in such cases, only the study that had published the primary data set was included in the meta-analysis); and v) presence of sufficient data to calculate an effect size ([@b23-mmr-16-05-6532]). For each included study, the following data were extracted by two independent investigators using standard forms: First author; journal; year of publication; study design; ethnicity of the subjects; sample size; phenotype information; genotype and allele distribution of subjects with and without AS ([@b24-mmr-16-05-6532]).

### Statistical analysis

Population-based studies were collected and subdivided into European and Asian ethnic populations. Data regarding the genotype and/or allele distributions are summarized in [Tables I](#tI-mmr-16-05-6532){ref-type="table"}--[IV](#tIV-mmr-16-05-6532){ref-type="table"}. The genotype and/or allele frequencies in these studies were analyzed using the EpiInfo™ program version 7.2 (Centers for Disease Control and Prevention, Atlanta, GA, USA; <http://www.cdc.gov/epiinfo>), and P\<0.05 was considered to indicate a statistically significant difference. Prior to the pooling procedure, Cochran\'s χ^2^-based Q-statistic, which was considered significant at P\<0.10, was performed to assess the heterogeneity within the group of odds ratios (ORs). The extent of the inconsistency across the studies was quantified using the I^2^ statistic, and I^2^\>50% was considered to be a large heterogeneity value among studies ([@b21-mmr-16-05-6532]). The natural logarithms of the OR estimates were determined using random-effect or fixed-effect models, depending on the heterogeneity among studies. The significance of the pooled ORs was determined using the Z-test. An ancillary procedure for funnel plot asymmetry was additionally used to qualitatively assess the evidence for publication bias. The above statistical analyses were performed using the RevMan software program (version 5.2; <http://www.cochrane.org/revman>) ([@b22-mmr-16-05-6532]).

### Structural and functional analysis

The functional effects of the non-synonymous variants of *ERAP1* were analyzed using the PolyPhen-2 software program (<http://genetics.bwh.harvard.edu/pph2/>), which is an automatic tool for predicting the possible effects of an amino acid substitution on the structure and function of a human protein. This prediction is based on a number of features contained in the sequence, as well as phylogenetic and structural information characterizing the substitution ([@b25-mmr-16-05-6532]). Further structural analysis was performed with the molecular visualization software PyMOL (version 1.5.0.4; Schrödinger, Inc., Portland, OR, USA), on the basis of the 2YD0 (<http://www.rcsb.org/pdb/explore.do?structureId=2yd0>) and 3MDJ (<http://www.rcsb.org/pdb/explore/literature.do?structureId=3MDJ>) Protein Data Bank (PDB) structures ([@b26-mmr-16-05-6532]).

Results
=======

### Available studies

In total, ≥89 studies were identified by the combined search. The reviews and studies written in languages other than English were excluded, leaving 63 studies. An additional 39 references that did not clearly meet the criteria or were not SNP association studies were further excluded. Therefore, a total of 24 studies remained. Nine additional references were excluded due to the fact that they did not supply the original data regarding genotypes and/or alleles in their samples ([@b2-mmr-16-05-6532],[@b8-mmr-16-05-6532],[@b27-mmr-16-05-6532]--[@b33-mmr-16-05-6532]), and one study was excluded due to the analysis of the same samples as previous studies ([Table I](#tI-mmr-16-05-6532){ref-type="table"}) ([@b34-mmr-16-05-6532]). Ultimately, a total of 14 studies contributed to available data regarding the following 13 identified SNPs in *ERAP1* associated with AS: Rs3734016, rs26653, rs27895, rs2287987, rs27434, rs30187, rs10050860, rs17482078, rs27044, rs1065407, rs27980, rs7711564 and rs27037 ([Table II](#tII-mmr-16-05-6532){ref-type="table"}) ([@b1-mmr-16-05-6532],[@b7-mmr-16-05-6532],[@b9-mmr-16-05-6532]--[@b20-mmr-16-05-6532]).

### Meta-analysis

A total of 9 studies, which included 7 studies involving subjects of European-descent and two studies involving subject of Asian descent, contributed 4,469 cases and 7,324 controls for the analysis of the association between the *ERAP1* SNP rs30187 and AS. Using a random-effects model, a significant difference was identified between the patients and controls for the T-allele of rs30187 (subtotal OR=1.27; 95% CI=1.15--1.40; Z=4.73; P\<1.0×10^−5^) in all of the samples combined, and significant evidence of between-study heterogeneity was identified among the group of allele-wise ORs (P=0.03; I^2^=54%; [Table III](#tIII-mmr-16-05-6532){ref-type="table"}). In addition, studies were analyzed separately by ethnicity (European and Asian) to limit the ethnic heterogeneity. The fixed-effects model was used for the European studies (P=0.53; I^2^=0%), and the random-effects model was used for the Asian studies (P=0.004, I^2^=82%) according to their heterogeneity tests. A statistically significant summary OR was identified in European studies (subtotal OR=1.29; 95% CI=1.17--1.41; Z=5.48; P\<1.0×10^−5^) and Asian studies (subtotal OR=1.31; 95% CI=1.06--1.63; Z=2.45; P=0.01; [Table III](#tIII-mmr-16-05-6532){ref-type="table"}).

The results of the publication bias tests for the rs30187 SNP are presented in [Fig. 1](#f1-mmr-16-05-6532){ref-type="fig"}. The results demonstrated that no publication bias existed in this group, as the shapes of the funnel plots did not reveal any obvious asymmetry.

A total of 5 studies involving European populations contributed 1,748 cases and 2,190 controls for the analysis of the association between the *ERAP1* SNP rs17482078 and AS. For the T-allele of rs17482078, no significant heterogeneity was detected (P=0.78; I^2^=0%). The fixed-effects summary OR was 0.73 (95% CI=0.65--0.82), and a significant association was observed (Z=5.25; P\<1.0×10^−5^; [Table III](#tIII-mmr-16-05-6532){ref-type="table"}). There was no evidence of publication bias in these 5 studies ([Fig. 2](#f2-mmr-16-05-6532){ref-type="fig"}).

Further meta-analyses were performed using the random-effects or fixed-effects models for rs3734016, rs26653, rs27895, rs2287987, rs27434, rs10050860, rs27044, rs1065407, rs27980, rs7711564 and rs27037 SNPs, according to the results of the heterogeneity test. The summary ORs for 8 SNPs (rs26653, rs2287987, rs27434, rs10050860, rs27044, rs27980, rs7711564 and rs27037) were statistically significant in the combined, European studies and Asian studies ([Table IV](#tIV-mmr-16-05-6532){ref-type="table"}). There was no evidence of publication bias for these SNPs in their associated studies (data not shown).

### Structural and functional analysis

A total of 9 SNPs (rs3734016, rs26653, rs27895, rs2287987, rs27434, rs30187, rs10050860, rs17482078 and rs27044) lead to a genetic variation within the coding region of the *ERAP1* gene. The PolyPhen-2 software program was used to predict the structural and functional effects of these variations on ERAP1, and the results are presented in [Table V](#tV-mmr-16-05-6532){ref-type="table"}. For rs30187 and rs17482078, the results of the functional prediction analysis suggested that these mutations were potentially damaging (scores 0.998 and 0.759, respectively). No predictions outside of the benign score range were identified for the remaining 6 SNPs (rs3734016, rs26653, rs27895, rs2287987, rs10050860 and rs27044). As the rs27434 SNP generates a synonymous substitution in exon 6, the PolyPhen-2 software was unable to analyze it ([Table V](#tV-mmr-16-05-6532){ref-type="table"}).

The crystal structure of ERAP1 revealed four protein domains and a large cavity between domains II and IV ([Figs. 3](#f3-mmr-16-05-6532){ref-type="fig"} and [4](#f4-mmr-16-05-6532){ref-type="fig"}) ([@b35-mmr-16-05-6532]). Domain I (residues 46--254; brown region, [Figs. 4](#f4-mmr-16-05-6532){ref-type="fig"} and [5](#f5-mmr-16-05-6532){ref-type="fig"}) is an all-β-sheet domain that docks above the thermolysin domain, caps the active site and provides binding sites for the N-terminus of a substrate peptide. Domain II (residues 255--529; purple region, [Figs. 3](#f3-mmr-16-05-6532){ref-type="fig"} and [4](#f4-mmr-16-05-6532){ref-type="fig"}) is the catalytic domain that possesses a zinc atom, the exo-peptidase specific G-A-M-E-N motif and the canonical zinc-binding motif (H-E-X-X-H-X~18~-E) on a thermolysin-like αβ fold. Domain III (residues 530--614; green region, [Figs. 3](#f3-mmr-16-05-6532){ref-type="fig"} and [4](#f4-mmr-16-05-6532){ref-type="fig"}) is composed of two β-sheets that forms a β-sandwich domain between domains II and IV. Domain IV (residues 615--940; blue region, [Figs. 3](#f3-mmr-16-05-6532){ref-type="fig"} and [4](#f4-mmr-16-05-6532){ref-type="fig"}) consisted solely of α-helices and displayed a bowl-like shape. In the closed state, domain IV arches over the catalytic domain and forms a large central cavity that completely obstructs the active site ([@b35-mmr-16-05-6532],[@b36-mmr-16-05-6532]).

ERAP1 is a multifunctional enzyme involved in cleaving peptides to an optimal length for presentation by MHC class I molecules. The crystal structures of ERAP1 display open and close states, and this enzyme is inactive in its open form ([@b36-mmr-16-05-6532]). The rs30187 SNP (K528R; yellow circles, [Fig. 3](#f3-mmr-16-05-6532){ref-type="fig"}) is located near the entrance of the substrate pocket and may affect substrate-binding affinity with the enzyme and reduce ERAP1 aminopeptidase activity toward a synthetic peptide substrate ([Fig. 3](#f3-mmr-16-05-6532){ref-type="fig"}) ([@b11-mmr-16-05-6532],[@b37-mmr-16-05-6532]). In addition, the rs17482078 SNP (R725Q; red circles, [Fig. 4](#f4-mmr-16-05-6532){ref-type="fig"}) is located on the inner surface of the C-terminal cavity and may affect the substrate sequence or length specificity ([@b35-mmr-16-05-6532]).

Protein structure prediction analysis provided evidence for the functional role of amino acid residue R725. Two hydrogen bonds were observed to form between R725 and D766 residues with distances of 3.1 Å and 3.2 Å in the closed form of ERAP1 ([Fig. 5](#f5-mmr-16-05-6532){ref-type="fig"}). Based on the aforementioned results and the molecular modeling structure of ERAP1, the R725Q SNP may therefore affect the stability of the C-terminus of ERAP1 in its active state.

Discussion
==========

In the present study, a two-stage bioinformatic analysis was performed to investigate the association between 13 SNPs in the *ERAP1* locus and AS using ethnically diverse independent samples from 14 previously published studies ([@b24-mmr-16-05-6532]). The functional effects of non-synonymous variations were analyzed with protein structure prediction analysis software, and the crystal structure of ERAP1 was examined using the PDB database.

For the rs30187 SNP, the p-value in the combined population was \<0.00001, suggesting an unequivocal association with AS. When the samples were stratified by ethnicity (European and Asian), the p-values for the association tests for this SNP remained significant (\<0.00001 and 0.02, respectively), thus providing additional evidence for the association of this SNP with AS in the two populations ([@b22-mmr-16-05-6532]). For the rs17482078 SNP, a significant association was observed in the European population (P\<0.00001), therefore suggesting an association of this SNP with AS. In addition, 11 additional SNPs (rs3734016, rs26653, rs27895, rs2287987, rs27434, rs10050860, rs27044, rs1065407, rs27980, rs7711564 and rs27037) were investigated to determine their association with AS. The summary ORs for 8 SNPs (rs26653, rs2287987, rs27434, rs10050860, rs27044, rs27980, rs7711564, and rs27037) were statistically significant in the combined, European and Asian studies when using the random-effects or fixed-effects models. However, prior to the meta-analysis, 10 studies investigating *ERAP1* and AS were excluded from the final statistical analysis due to limited available data. All of the excluded studies also demonstrated significant associations in the above 13 SNPs between the case and control populations (data not shown). These results provided further evidence of an association between *ERAP1* and AS. Therefore, the results of the present study suggest that *ERAP1* may be an important susceptibility gene for AS, which is consistent with the results from a number of previously published studies ([@b1-mmr-16-05-6532],[@b7-mmr-16-05-6532],[@b10-mmr-16-05-6532],[@b12-mmr-16-05-6532],[@b14-mmr-16-05-6532],[@b18-mmr-16-05-6532],[@b20-mmr-16-05-6532],[@b27-mmr-16-05-6532],[@b30-mmr-16-05-6532],[@b32-mmr-16-05-6532],[@b38-mmr-16-05-6532]--[@b40-mmr-16-05-6532]).

The *ERAP1* gene is located on chromosome 5q15 and is translated into two isoforms comprising 941 and 948 amino acids, which are generated via alternative splicing. The active site of ERAP1 spans 375 amino acids ([@b41-mmr-16-05-6532]). Although ERAP1 does not contain any obvious endoplasmic reticulum (ER) retention motifs, as identified in additional ER resident proteins, it is known to localize within the ER; however, exon 10 may serve a role in ER retention ([@b42-mmr-16-05-6532]). ERAP1 is known to have two major functions. Firstly, it is involved in cleaving peptides to the optimal length for MHC class I presentation, and secondly, it cleaves different cell surface cytokine receptors, including tumor necrosis factor receptor 1, interleukin (IL)-1 receptor II and IL-6 receptor α ([@b43-mmr-16-05-6532]).

A previous meta-analysis investigated the potential molecular mechanisms underlying the effect of different genetic variants of *ERAP 1*in the development of AS ([@b40-mmr-16-05-6532]). Goto *et al* ([@b37-mmr-16-05-6532]) demonstrated that a K528R substitution resulted in reduced ERAP1 enzymatic activity by reducing the hydrolysis of the bioactive hormones, angiotensin II and kallidin ([@b37-mmr-16-05-6532],[@b42-mmr-16-05-6532]). In addition, these authors identified little difference between the activities of the N575 and E730 mutants when compared with the wild-type (WT), and their results were consistent with the PolyPhen-2 prediction analysis performed in the present study ([@b42-mmr-16-05-6532]). The potentially damaging substitution at R528 (rs30187) has been well documented, and similar results among studies have indicated a 30--40% reduction in enzymatic activity compared with that of the WT ([@b34-mmr-16-05-6532]--[@b37-mmr-16-05-6532],[@b44-mmr-16-05-6532]). K528R is located near the entrance of the substrate pocket, and may contribute to substrate-binding affinity, thus leading to reduced ERAP1 aminopeptidase activity with a synthetic peptide substrate ([@b37-mmr-16-05-6532]).

It is hypothesized that Q725 (rs17482078) is an additional potentially damaging substitution, and various *in vitro* studies have suggested that it decreases the enzymatic activity by 40% compared with that of the WT ([@b34-mmr-16-05-6532],[@b37-mmr-16-05-6532]). The protein structure analysis performed in the present study, suggested that this substitution may result the disruption of two hydrogen bonds between R725 and D766 in the active state of ERAP1 and affect the stability of the C-terminus. Based on these alterations, a decrease in the enzymatic activity induced by the substitution of R to Q at position 725 may be expected. However, in the present study, the results of the meta-analysis at stage 1 suggested the opposite, as the minor allele of rs17482078 (Q725) was observed to theoretically decrease the risk of AS in the case-control studies involving different populations. Due to the limited understanding of the association between the structure and function of ERAP1, a simple interpretation of the role of rs17482078 is therefore not possible at this stage. Therefore, as further studies emerge, the current findings may be updated and more reliable estimates of the role of this SNP may be obtained.

In conclusion, the results of the two-stage bioinformatics analysis performed in the current study suggested that *ERAP1* may present an important susceptibility gene for AS, and revealed two functional SNPs (rs30187 and rs17482078) that may decrease the enzymatic activity of ERAP1 by affecting its protein structure. Therefore, future studies investigating the role of these ERAP1 variants in influencing protein structure are warranted.
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![Funnel plots depicting the publication bias of association studies for the ankylosing spondylitis-associated rs30187 single nucleotide polymorphism in the endoplasmic reticulum aminopeptidase 1 gene in (A) combined, (B) Asian and (C) European populations. OR, odds ratio; SE, significant effects.](mmr-16-05-6532-g00){#f1-mmr-16-05-6532}

![A funnel plot depicting the publication bias of association studies involving the ankylosing spondylitis-associated rs17482078 SNP in the Meta-analysis of the association studies for SNP rs17482078 in the endoplasmic reticulum aminopeptidase 1 gene. OR, odds ratio; SE, significant effects; SNP, single nucleotide polymorphism.](mmr-16-05-6532-g01){#f2-mmr-16-05-6532}

![Structure of the human ERAP1 protein and the location of the K528R single nucleotide polymorphism (yellow). (A) Open and (B) closed forms of ERAP1. The four domains of ERAP1 are indicated as follows: Domain I, brown; domain II, purple; domain III, green; domain IV, blue. ERAP1, endoplasmic reticulum aminopeptidase 1.](mmr-16-05-6532-g02){#f3-mmr-16-05-6532}

![Structure of the human ERAP1 protein and the location of the R725Q single nucleotide polymorphism (red). (A) Open and (B) closed forms of ERAP1. The four domains of ERAP1 are indicated as follows: Domain I, brown; domain II, purple; domain III, green; domain IV, blue. ERAP1, endoplasmic reticulum aminopeptidase 1.](mmr-16-05-6532-g03){#f4-mmr-16-05-6532}

![Depiction of two hydrogen bonds between R725 and D766 amino acid residues, with distances of 3.1 Å and 3.2 Å, in the closed form endoplasmic reticulum aminopeptidase 1. The nitrogen atoms are indicated in blue and the oxygen atoms are indicated in red.](mmr-16-05-6532-g04){#f5-mmr-16-05-6532}

###### 

Summary of the association studies published up to June 2016 investigating the SNPs in *ERAP1* and AS.

  Author, year                        Country    Ethnicity   Cases   Controls   No. of studied SNPs   Number of positive SNPs^[a](#tfn1-mmr-16-05-6532){ref-type="table-fn"}^   Detailed data   Quality control of current meta-analysis   (Refs.)
  ----------------------------------- ---------- ----------- ------- ---------- --------------------- ------------------------------------------------------------------------- --------------- ------------------------------------------ --------------------------
  WTCCC, 2007                         UK         European    922     1,500        7                     5                                                                       Yes             Included                                     ([@b7-mmr-16-05-6532])
                                      USA        European    471     625          4                     4                                                                       No              Excluded                                     ([@b7-mmr-16-05-6532])
  Davidson SI, *et al*, 2009          China      Asian       527     945        33                      7                                                                       Yes             Included                                   ([@b20-mmr-16-05-6532])
  Zvyagin IV, *et al*, 2010           Russia     European    84      77           5                     3                                                                       Yes             Included                                     ([@b9-mmr-16-05-6532])
  Pazar B, *et al*, 2010              Hungary    European    297     200          5                     4                                                                       Yes             Included                                   ([@b10-mmr-16-05-6532])
  Szczypiorska M, *et al*, 2011       Spain      European    300     300          8                     5                                                                       Yes             Included                                   ([@b11-mmr-16-05-6532])
  Bang SY, *et al*, 2011              Korea      Asian       1,164   752          2                     2                                                                       Yes             Included                                   ([@b12-mmr-16-05-6532])
  Lin Z, *et al*, 2012                China      Asian       1,837   4,231        2                     2                                                                       Yes             Included                                     ([@b1-mmr-16-05-6532])
  Mahmoudi M, *et al*, 2012           Iran       Asian       387     316          4                     2                                                                       Yes             Included                                   ([@b13-mmr-16-05-6532])
  Wu W, *et al*, 2012                 China      Asian       328     627          1                     1                                                                       Yes             Included                                   ([@b16-mmr-16-05-6532])
  Cinar M, *et al*, 2013              Turkey     European    150     150        10                      1                                                                       Yes             Included                                   ([@b18-mmr-16-05-6532])
  Cherciu M, *et al*, 2013            Romania    European    137     139          2                     1                                                                       Yes             Included                                   ([@b17-mmr-16-05-6532])
  Zhang Z, *et al*, 2014              China      Asian       602     619          4                     1                                                                       Yes             Included                                   ([@b19-mmr-16-05-6532])
  Chen C, *et al*, 2015               China      Asian       368     460          6                     4                                                                       Yes             Included                                   ([@b14-mmr-16-05-6532])
  Wang J, *et al*, 2015               China      Asian       100     100          2                     1                                                                       Yes             Included                                   ([@b15-mmr-16-05-6532])
  Maksymowych WP, *et al*, 2009       Canada     European    992     1,437        6                     3                                                                       No              Excluded                                   ([@b8-mmr-16-05-6532])
  Pimentel-Santos FM, *et al*, 2009   Portugal   European    358     285          5                     2                                                                       No              Excluded                                   ([@b27-mmr-16-05-6532])
  Harvey D, *et al*, 2009             UK         European    730     1,021        4                     4                                                                       No              Excluded                                   ([@b28-mmr-16-05-6532])
                                      UK         European    1,604   1,021      23                    11                                                                        No              Excluded                                   ([@b28-mmr-16-05-6532])
  Choi CB, *et al*, 2010              Korea      Asian       872     403          5                     2                                                                       No              Excluded                                   ([@b29-mmr-16-05-6532])
  Reveille JD, *et al*, 2010          Mixed      European    2,053   5,140        2                     2                                                                       No              Excluded                                   ([@b30-mmr-16-05-6532])
                                      UK         European    898     1,518        2                     2                                                                       No              Excluded                                   ([@b30-mmr-16-05-6532])
  Li C, *et al*, 2010                 China      Asian       471     456          6                     2                                                                       No              Excluded                                   ([@b31-mmr-16-05-6532])
  TASC, 2011                          Mixed      European    1,787   4,800        2                     1                                                                       No              Excluded                                   ([@b34-mmr-16-05-6532])
                                      Mixed      European    3,023   8,779        2                     1                                                                       No              Excluded                                   ([@b34-mmr-16-05-6532])
                                      Mixed      European    2,111   4,483        2                     2                                                                       No              Excluded                                   ([@b34-mmr-16-05-6532])
  Wang CM, *et al*, 2012              China      Asian       797     1,150        4                     4                                                                       No              Excluded                                   ([@b32-mmr-16-05-6532])
  Kadi A, *et al*, 2013               France     European    180     384          3                     1                                                                       No              Excluded                                     ([@b2-mmr-16-05-6532])
                                      Belgium    European    256     248          3                     2                                                                       No              Excluded                                     ([@b2-mmr-16-05-6532])
  Liu Y, *et al*, 2015                China      Asian       707     837          8                     5                                                                       No              Excluded                                   ([@b33-mmr-16-05-6532])

Positive SNPs at P\<0.05. AS, ankylosing spondylitis; SNPs, single nucleotide polymorphisms; *ERAP1*, endoplasmic reticulum aminopeptidase 1 gene; WTCCC, Wellcome Trust Case Control Consortium; TASC, The Australo-Anglo-American Spondyloarthritis Consortium.

###### 

Details of the AS-associated SNPs in *ERAP1* identified in the association studies.

                                                            Genotypes for cases   Genotypes for controls         Minor allele:major allele                                                                                                                                                                           
  --------------------------------- --------- ------------- --------------------- ------------------------ ----- --------------------------- ------- ------- ------------------------------------------------------------- ------------- ------------- ------------------------------------------------------------- --------------------------
  rs3734016(A/G), 96,803,761                                                                                                                                                                                                                                                                                         
    WTCCC, 2007                     UK        922/1,500     0                     93                       829   4                           137     1,325   2.40×10^−1^                                                   93:1,751      145:2,787     8.80×10^−1^                                                     ([@b7-mmr-16-05-6532])
    Davidson SI, *et al*, 2009      China     527/945       6                     126                      358   24                          228     593     1.25×10^−1^                                                   138:842       276:1,414     1.22×10^−1^                                                   ([@b20-mmr-16-05-6532])
  rs26653(C/G), 96,803,547                                                                                                                                                                                                                                                                                           
    Szczypiorska M, *et al*, 2011   Spain     300/300       40                    130                      119   25                          125     138     8.40×10^−2^                                                   210:368       175:401       3.20×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b11-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       36                    78                       36    21                          73      56      1.50×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     150:150       115:185       4.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b18-mmr-16-05-6532])
  rs27895(A/G), 96,793,840                                                                                                                                                                                                                                                                                           
    WTCCC, 2007                     UK        922/1,500     3                     132                      787   6                           184     1,276   4.44×10^−1^                                                   138:1,706     196:2,736     2.92×10^−1^                                                     ([@b7-mmr-16-05-6532])
    Szczypiorska M, *et al*, 2011   Spain     300/300       1                     36                       258   2                           29      265     5.55×10^−1^                                                   38:552        33:559        5.31×10^−1^                                                   ([@b11-mmr-16-05-6532])
  rs2287987(C/T), 96,793,832                                                                                                                                                                                                                                                                                         
    WTCCC, 2007                     UK        922/1,500     16                    293                      611   83                          481     893     6.86×10^−6[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     325:1,515     647:2,267     1.57×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b7-mmr-16-05-6532])
    Zvyagin IV, *et al*, 2010       Russia    84/77         1                     13                       70    3                           26      44      5.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     15:153        32:114        1.30×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b9-mmr-16-05-6532])
    Pazar B, *et al*, 2010          Hungary   297/200       4                     93                       200   14                          72      114     1.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     101:493       100:300       2.10×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b10-mmr-16-05-6532])
    Szczypiorska M, *et al*, 2011   Spain     300/300       6                     83                       204   10                          104     182     1.00×10^−1^                                                   95:491        124:468       3.70×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b11-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       2                     22                       126   1                           38      111     6.20×10^−2^                                                   26:274        40:260        6.80×10^−2^                                                   ([@b18-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            47:689        73:847        2.27×10^−1^                                                   ([@b14-mmr-16-05-6532])
  rs27434(G/A), 96,793,809                                                                                                                                                                                                                                                                                           
    Davidson SI, *et al*, 2009      China     527/945       99                    259                      121   206                         418     195     1.84×10^−1^                                                   457:501       830:808       1.45×10^−1^                                                   ([@b20-mmr-16-05-6532])
    Bang SY, *et al*, 2011          Korea     1,164/752     198                   626                      295   216                         336     167     \<1.00×10^−8[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^   1,022:1,216   768:670       4.60×10^−6[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b12-mmr-16-05-6532])
    Lin Z, *et al*, 2012            China     1,837/4,231   331                   980                      526   941                         2,126   1,163   9.60×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     1,642:2,032   4,008:4,452   6.50×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b1-mmr-16-05-6532])
    Mahmoudi M, *et al*, 2012       Iran      387/316       138                   188                      55    147                         141     28      7.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     464:298       435:197       2.10×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b13-mmr-16-05-6532])
    Zhang Z, *et al*, 2014          China     602/619       165                   311                      125   157                         287     165     3.60×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     641:561       601:617       5.00×10^−2^                                                   ([@b19-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            230:506       476:444       \<1.0×10^−8[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^    ([@b14-mmr-16-05-6532])
    Wang J, *et al*, 2015           China     100/100       22                    49                       29    37                          42      21      6.00×10^−2^                                                   93:107        116:84        2.10×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b15-mmr-16-05-6532])
  rs30187(T/C), 96,788,627                                                                                                                                                                                                                                                                                           
    WTCCC, 2007                     UK        922/1,500     134                   472                      316   177                         627     662     9.50×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     740:1104      981:1,951     2.90×10^−6[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b7-mmr-16-05-6532])
    Zvyagin IV, *et al*, 2010       Russia    84/77         7                     48                       29    9                           33      35      1.93×10^−1^                                                   62:106        51:103        4.78×10^−1^                                                   ([@b9-mmr-16-05-6532])
    Pazar B, *et al*, 2010          Hungary   297/200       45                    136                      116   26                          76      98      8.90×10^−2^                                                   226:368       128:272       5.10×10^−2^                                                   ([@b10-mmr-16-05-6532])
    Szczypiorska M, *et al*, 2011   Spain     300/300       57                    162                      74    46                          144     99      5.40×10^−2^                                                   276:310       236:342       3.10×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b11-mmr-16-05-6532])
    Lin Z, *et al*, 2012            China     1,837/4,231   528                   979                      330   1,164                       2,130   937     1.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     2,035:1,639   4,458:4,004   6.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b1-mmr-16-05-6532])
    Mahmoudi M, *et al*, 2012       Iran      387/316       103                   190                      88    45                          163     104     6.00×10^−5[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     396:366       253:371       2.30×10^−5[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b13-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       36                    85                       29    29                          103     18      8.00×10^−2^                                                   157:143       161:139       7.44×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Cherciu M, *et al*, 2013        Romania   137/139       14                    80                       43    15                          59      65      2.20×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     108:166       89:189        7.00×10^−2^                                                   ([@b17-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            412:324       446:474       2.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b14-mmr-16-05-6532])
  rs10050860(T/C), 96,786,506                                                                                                                                                                                                                                                                                        
    WTCCC, 2007                     UK        922/1,500     17                    296                      609   86                          489     891     6.11×10^−6[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     330:1514      661:2,271     1.15×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b7-mmr-16-05-6532])
    Zvyagin IV, *et al*, 2010       Russia    84/77         0                     18                       66    5                           26      46      8.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     18:140        36:118        2.40×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b9-mmr-16-05-6532])
    Pazar B, *et al*, 2010          Hungary   297/200       4                     87                       206   14                          64      122     2.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     95:499        92:308        5.60×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b10-mmr-16-05-6532])
    Szczypiorska M, *et al*,2011    Spain     300/300       6                     82                       205   11                          100     180     8.80×10^−2^                                                   94:492        122:460       3.00×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b11-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       5                     27                       118   3                           44      103     6.10×10^−2^                                                   37:263        50:250        1.32×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            37:699        186:734       \<1.00×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^   ([@b14-mmr-16-05-6532])
  rs17482078(T/C), 96,783,162                                                                                                                                                                                                                                                                                        
    WTCCC, 2007                     UK        922/1,500     16                    285                      621   78                          476     912     2.40×10^−5[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     317:1,527     632:2,300     2.30×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b7-mmr-16-05-6532])
    Zvyagin IV, *et al*, 2010       Russia    84, 77        2                     17                       65    3                           27      47      7.90×10^−2^                                                   21:147        33:121        3.20×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b9-mmr-16-05-6532])
    Pazar B, *et al*, 2010          Hungary   297/200       5                     85                       207   13                          58      129     1.70×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     95:499        84:316        4.40×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b10-mmr-16-05-6532])
    Szczypiorska M, *et al*, 2011   Spain     300/300       7                     82                       206   12                          100     185     1.21×10^−1^                                                   96:494        124:470       4.20×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b11-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       2                     23                       125   1                           39      110     6.70×10^−2^                                                   27:273        41:259        7.20×10^−2^                                                   ([@b18-mmr-16-05-6532])
  rs27044(G/C), 96,783,148                                                                                                                                                                                                                                                                                           
    WTCCC, 2007                     UK        922/1,500     94                    432                      395   119                         553     793     6.20×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     620:1,222     791:2,139     9.00×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^       ([@b7-mmr-16-05-6532])
    Zvyagin IV, *et al*, 2010       Russia    84/77         7                     42                       35    9                           26      42      1.13×10^−1^                                                   56:112        44:110        3.57×10^−1^                                                   ([@b9-mmr-16-05-6532])
    Pazar B, *et al*, 2010          Hungary   297/200       27                    136                      134   14                          60      126     4.30×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     190:404       88:312        5.90×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b10-mmr-16-05-6532])
    Szczypiorska M, *et al*, 2011   Spain     300/300       34                    149                      109   35                          127     132     1.38×10^−1^                                                   217:367       197:391       1.91×10^−1^                                                   ([@b11-mmr-16-05-6532])
    Wu W, *et al*, 2012             China     328/627       48                    156                      178   285                         252     90      \<1.00×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^   252:512       822:432       \<1.00×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^   ([@b16-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       19                    67                       64    12                          71      67      4.14×10^−1^                                                   105:195       95:205        3.87×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Cherciu M, *et al*, 2013        Romania   137/139       9                     66                       62    7                           50      82      7.40×10^−2^                                                   84:190        64:214        4.30×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b17-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            361:375       431:489       3.73×10^−1^                                                   ([@b14-mmr-16-05-6532])
  rs1065407(C/A), 96,776,379                                                                                                                                                                                                                                                                                         
    Davidson SI, *et al*, 2009      China     527/945       0                     52                       439   3                           74      767     2.33×10^−1^                                                   52:930        80:1,608      5.23×10^−1^                                                   ([@b20-mmr-16-05-6532])
    Chen C, *et al*, 2015           China     368/460       NA                    NA                       NA    NA                          NA      NA      NA                                                            52:684        172:748       \<1.00×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^   ([@b14-mmr-16-05-6532])
  rs27980(C/A), 96,762,191                                                                                                                                                                                                                                                                                           
    Davidson SI, *et al*, 2009      China     527/945       87                    252                      152   211                         407     227     8.00×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     426:556       829:861       4.60×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b20-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       11                    68                       71    13                          67      70      9.13×10^−1^                                                   90:210        93:207        7.90×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Zhang Z, *et al*, 2014          China     602/619       125                   294                      179   140                         293     182     7.27×10^−1^                                                   544:652       573:657       5.87×10^−1^                                                   ([@b19-mmr-16-05-6532])
  rs7711564(G/C), 96,760,515                                                                                                                                                                                                                                                                                         
    Davidson SI, *et al*, 2009      China     527/945       88                    249                      150   209                         405     226     1.40×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     425:549       823:857       7.70×10^−3[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b20-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       4                     60                       86    10                          56      84      2.55×10^−1^                                                   68:232        76:224        4.45×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Wang J, *et al*, 2015           China     100/100       28                    59                       13    41                          53      6       6.90×10^−2^                                                   115:85        135:65        3.90×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b15-mmr-16-05-6532])
  rs27037(T/G), 96,758,990                                                                                                                                                                                                                                                                                           
    Davidson SI, *et al*, 2009      China     527/945       97                    258                      135   139                         402     285     2.80×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     452:528       680:972       1.30×10^−2[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b20-mmr-16-05-6532])
    Bang SY, *et al*, 2011          Korea     1,164/752     142                   578                      403   89                          280     343     3.20×10^−7[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     862:1,384     458:966       1.30×10^−4[a](#tfn2-mmr-16-05-6532){ref-type="table-fn"}^     ([@b12-mmr-16-05-6532])
    Cinar M, *et al*, 2013          Turkey    150/150       5                     77                       68    1                           71      78      1.66×10^−1^                                                   87:213        73:227        1.97×10^−1^                                                   ([@b18-mmr-16-05-6532])
    Zhang Z, *et al*, 2014          China     602/619       99                    295                      201   94                          296     224     5.83×10^−1^                                                   493:697       484:744       3.13×10^−1^                                                   ([@b19-mmr-16-05-6532])

P\<0.05. AS, ankylosing spondylitis; SNPs, single nucleotide polymorphisms; *ERAP1*, endoplasmic reticulum aminopeptidase 1 gene; WTCCC, Wellcome Trust Case Control Consortium; NA, not applicable.

###### 

Fixed- and random-effects model summary OR and 95% CI values for the *ERAP1* SNPs, rs30187 and rs17482078, associated with AS risk.

                                         Heterogeneity test   Fixed-effects model   Random-effects model                                                                     
  ------------------ ----- ------------- -------------------- --------------------- ------------------------------------------------------------- ------------------- ------ -------------------------------------------------------------
  rs30187 (T)                                                                                                                                                                
    Combined (9/9)   54    3.0×10^−2^                                                                                                             1.27 (1.15--1.40)   4.73   \<1.00×10^−5[a](#tfn3-mmr-16-05-6532){ref-type="table-fn"}^
    Asian (3/3)      82    4.0×10^−3^                                                                                                             1.31 (1.06--1.63)   2.45   1.00×10^−2[a](#tfn3-mmr-16-05-6532){ref-type="table-fn"}^
    European (6/6)     0   5.3×10^−1^    1.29 (1.17--1.41)    5.48                  \<1.00×10^−5[a](#tfn3-mmr-16-05-6532){ref-type="table-fn"}^                              
  rs17482078 (T)                                                                                                                                                             
    European (5/5)     0   7.80×10^−1^   0.73 (0.65--0.82)    5.25                  \<1.00×10^−5[a](#tfn3-mmr-16-05-6532){ref-type="table-fn"}^                              

P\<0.05. OR, odds ratio; CI, confidence interval; *ERAP1*, endoplasmic reticulum aminopeptidase 1 gene; AS, ankylosing spondylitis; SNPs, single nucleotide polymorphisms.

###### 

Fixed-effects and random-effects model summary OR and 95% CI values for 11 *ERAP1* SNPs associated with AS risk.

                     Heterogeneity test   Fixed-effects model                                          Random-effects model                                                                                                    
  ------------------ -------------------- ------------------------------------------------------------ ---------------------- ------ -------------------------------------------------------------- ------------------- ------ -----------------------------------------------------------
  rs3734016 (A)                                                                                                                                                                                                                
    Combined (2/2)   18                   2.70×10^−1^                                                  0.91 (0.77--1.08)      1.11   2.70×10^−1^                                                                               
  rs26653 (C)                                                                                                                                                                                                                  
    European (2/2)     0                  3.20×10^−1^                                                  1.41 (1.16--1.71)      3.44   6.0×10^−4[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                  
  rs27895 (A)                                                                                                                                                                                                                  
    European (2/2)     0                  9.10×10^−1^                                                  1.14 (0.93--1.39)      1.22   2.20×10^−1^                                                                               
  rs2287987 (C)                                                                                                                                                                                                                
  Combined (6/6)     23                   2.60×10^−1^                                                  0.71 (0.64--0.79)      6.00   \<1.00×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                               
    European (5/5)   35                   1.90×10^−1^                                                  0.70 (0.63--0.79)      5.91   \<1.00×10^−5^                                                                             
  rs27434 (G)                                                                                                                                                                                                                  
    Asian (7/7)      92                   \<1.0×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                                                                                0.76 (0.62--0.93)   2.62   9.00×10^−3[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^
  rs10050860 (T)                                                                                                                                                                                                               
  Combined (6/6)     88                   \<1.0×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                                                                                0.53 (0.36--0.78)   3.24   1.00×10^−3[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^
    European (5/5)   11                   3.4×10^−1^                                                   0.71 (0.63--0.80)      5.80   \<1.00×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                               
  rs27044 (G)                                                                                                                                                                                                                  
  Combined (8/8)     97                   \<1.0×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                                                                                1.06 (0.65--1.71)   0.22   8.20×10^−1^
    Asian (2/2)      99                   \<1.0×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                                                                                0.53 (0.13--2.18)   0.88   3.80×10^−1^
    European (6/6)     0                  4.90×10^−1^                                                  1.35 (1.23--1.49)      6.24   \<1.00×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                               
  rs1065407 (C)                                                                                                                                                                                                                
    Asian (2/2)      96                   \<1.0×10^−5[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                                                                                0.61 (0.18--2.02)   0.81   4.20×10^−1^
  rs27980 (C)                                                                                                                                                                                                                  
  Combined (3/3)     29                   2.50×10^−1^                                                  0.88 (0.79--0.98)      2.36   2.00×10^−2[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                 
    Asian (2/2)      61                   1.10×10^−1^                                                  0.87 (0.78--0.98)      2.40   2.00×10^−2[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                 
  rs7711564 (G)                                                                                                                                                                                                                
  Combined (3/3)       0                  5.70×10^−1^                                                  0.79 (0.69--0.91)      3.29   1.00×10^−3[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                 
    Asian (2/2)        0                  3.40×10^−1^                                                  0.78 (0.68--0.91)      3.23   1.00×10^−3[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                                 
  rs27037 (T)                                                                                                                                                                                                                  
  Combined (4/4)       2                  3.80×10^−1^                                                  1.22 (1.12--1.33)      4.53   \<1.00×10^−5a[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                              
    Asian (3/3)      33                   2.20×10^−1^                                                  1.22 (1.11--1.33)      4.34   \<1.00×10^−4a[a](#tfn4-mmr-16-05-6532){ref-type="table-fn"}^                              

P\<0.05. OR, odds ratio; CI, confidence interval; *ERAP1*, endoplasmic reticulum aminopeptidase 1 gene; AS, ankylosing spondylitis; SNPs, single nucleotide polymorphisms.

###### 

Predicted effects of the identified SNPs on *ERAP1* protein function.

  ERAP1 SNP    Genomic coordinates (bp)   Amino acid sequence alteration or gene location   PolyPhen-2 phenotype prediction   Score
  ------------ -------------------------- ------------------------------------------------- --------------------------------- -------
  rs3734016    96,803,761                 E56K                                              Benign                            0.008
  rs26653      96,803,547                 R127P                                             Benign                            0.000
  rs27895      96,793,840                 G346D                                             Benign                            0.016
  rs2287987    96,793,832                 M349V                                             Benign                            0.203
  rs27434      96,793,809                 A356A                                             --                                --
  rs30187      96,788,627                 K528R                                             Probably damaging                 0.998
  rs10050860   96,786,506                 D575N                                             Benign                            0.000
  rs17482078   96,783,162                 R725Q                                             Probably damaging                 0.759
  rs27044      96,783,148                 Q730E                                             Benign                            0.038
  rs1065407    96,776,379                 Intron                                            --                                --
  rs27980      96,762,191                 3′-UTR                                            --                                --
  rs7711564    96,760,515                 Proximal to the 3′-end of *ERAP1*                 --                                --
  rs27037      96,758,990                 Proximal to the 3′-end of *ERAP1*                 --                                --

SNPs, single nucleotide polymorphisms; *ERAP1*, endoplasmic reticulum aminopeptidase 1 gene; UTR, untranslated region.
